275 related articles for article (PubMed ID: 25641881)
1. Successful use of brentuximab vedotin for refractory anaplastic large cell lymphoma as a bridging therapy to haploidentical stem cell transplantation and maintenance therapy post-transplantation.
Koh KN; Im HJ; Suh JK; Lee SW; Choi ES; Seo JJ
Pediatr Blood Cancer; 2015 Jun; 62(6):1063-5. PubMed ID: 25641881
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma.
Ishizawa K; Yanai T
Adv Ther; 2019 Oct; 36(10):2679-2696. PubMed ID: 31392578
[TBL] [Abstract][Full Text] [Related]
3. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.
Mediwake H; Morris K; Curley C; Butler J; Kennedy G
Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950
[TBL] [Abstract][Full Text] [Related]
4. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
5. Brentuximab vedotin (SGN-35) in a 3-year-old child with relapsed systemic anaplastic large cell lymphoma.
Mikles B; Levine J; Gindin T; Bhagat G; Satwani P
J Pediatr Hematol Oncol; 2014 Mar; 36(2):e85-7. PubMed ID: 23588340
[TBL] [Abstract][Full Text] [Related]
6. Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin.
Chihara D; Wong S; Feldman T; Fanale MA; Sanchez L; Connors JM; Savage KJ; Oki Y
Hematol Oncol; 2019 Feb; 37(1):35-38. PubMed ID: 30209819
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
Illidge T; Bouabdallah R; Chen R; Gopal AK; Moskowitz CH; Ramchandren R; Shustov AR; Tilly H; Trippett TM; Gibb A; Grove LE; Advani R
Leuk Lymphoma; 2015 Mar; 56(3):703-10. PubMed ID: 24913507
[TBL] [Abstract][Full Text] [Related]
8. [Allogeneic hematopoietic stem cell transplantation following treatment with brentuximab vedotin for refractory Hodgkin lymphoma].
Yamane Y; Koda Y; Kohashi S; Kato J; Hashida R; Sakurai M; Toyama T; Kikuchi T; Okayama M; Kasahara H; Karigane D; Shimizu T; Okamoto S; Mori T
Rinsho Ketsueki; 2017; 58(7):755-759. PubMed ID: 28781270
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients.
Gandolfi L; Pellegrini C; Casadei B; Stefoni V; Broccoli A; Tonialini L; Morigi A; Argnani L; Zinzani PL
Oncologist; 2016 Dec; 21(12):1436-1441. PubMed ID: 27486201
[TBL] [Abstract][Full Text] [Related]
10. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.
Locatelli F; Mauz-Koerholz C; Neville K; Llort A; Beishuizen A; Daw S; Pillon M; Aladjidi N; Klingebiel T; Landman-Parker J; Medina-Sanson A; August K; Sachs J; Hoffman K; Kinley J; Song S; Song G; Zhang S; Suri A; Gore L
Lancet Haematol; 2018 Oct; 5(10):e450-e461. PubMed ID: 30290902
[TBL] [Abstract][Full Text] [Related]
11. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center.
Gibb A; Jones C; Bloor A; Kulkarni S; Illidge T; Linton K; Radford J
Haematologica; 2013 Apr; 98(4):611-4. PubMed ID: 23065511
[TBL] [Abstract][Full Text] [Related]
12. [Brentuximab vedotin: new treatment for CD30+ lymphomas].
Terriou L; Bonnet S; Debarri H; Demarquette H; Morschhauser F
Bull Cancer; 2013; 100(7-8):775-9. PubMed ID: 23831822
[TBL] [Abstract][Full Text] [Related]
13. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
Oregel KZ; Everett E; Zhang X; Nagaraj G
Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents--a Berlin-Frankfurt-Münster group report.
Woessmann W; Peters C; Lenhard M; Burkhardt B; Sykora KW; Dilloo D; Kremens B; Lang P; Führer M; Kühne T; Parwaresch R; Ebell W; Reiter A
Br J Haematol; 2006 Apr; 133(2):176-82. PubMed ID: 16611309
[TBL] [Abstract][Full Text] [Related]
15. [Durable remission attained by long-term brentuximab vedotin administration in a relapsed post-allogeneic bone marrow transplant Hodgkin lymphoma patient].
Ono Y; Hiramoto N; Yoshioka S; Yabushita T; Koba Y; Tabata S; Imai Y; Ishikawa T
Rinsho Ketsueki; 2017; 58(12):2397-2401. PubMed ID: 29332873
[TBL] [Abstract][Full Text] [Related]
16. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.
Foyil KV; Bartlett NL
Cancer J; 2012; 18(5):450-6. PubMed ID: 23006951
[TBL] [Abstract][Full Text] [Related]
17. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma.
Garciaz S; Coso D; Peyrade F; Fürst S; Duran S; Chetaille B; Brenot-Rossi I; Devillier R; Granata A; Blaise D; Bouabdallah R
Hematol Oncol; 2014 Dec; 32(4):187-91. PubMed ID: 24301099
[TBL] [Abstract][Full Text] [Related]
18. [Successful bridging therapy with alectinib prior to allogeneic stem cell transplantation for refractory ALK-positive anaplastic large cell lymphoma].
Kono A; Tanaka K; Shimada T; Bando K; Takahata A; Koi S; Yamamoto M; Mori T; Toyota S
Rinsho Ketsueki; 2024; 65(3):158-163. PubMed ID: 38569859
[TBL] [Abstract][Full Text] [Related]
19. Brentuximab vedotin in anaplastic large cell lymphoma.
Skarbnik AP; Smith MR
Expert Opin Biol Ther; 2012 May; 12(5):633-9. PubMed ID: 22449148
[TBL] [Abstract][Full Text] [Related]
20. Haematopoietic stem cell transplantation for relapsed or refractory anaplastic large cell lymphoma: a study of children and adolescents in Japan.
Fukano R; Mori T; Kobayashi R; Mitsui T; Fujita N; Iwasaki F; Suzumiya J; Chin M; Goto H; Takahashi Y; Hara J; Park YD; Inoue M; Koga Y; Inagaki J; Sakamaki H; Adachi S; Kawa K; Kato K; Suzuki R
Br J Haematol; 2015 Feb; 168(4):557-63. PubMed ID: 25312752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
